Gland PharmaNSE:GLAND -0.49%83 EBITDA Margin % is 35.83% as of Mar. 2026, which is 3% below its 10-year median of 36.90. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,124.86 (Fairly Valued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Gland Pharma ranks better than 86.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gland Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹6,245 Mil. Gland Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹17,428 Mil. Therefore, Gland Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 35.83%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gland Pharma EBITDA Margin % Related Terms
Gland Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a EBITDA Margin % of 35.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gland Pharma and its competitors. This is near median its historical median of 36.90. Over the past decade, Gland Pharma's EBITDA Margin % has ranged from 26.40 to 42.53. According to the industry distribution chart, Gland Pharma ranks #133 out of 955 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Gland Pharma's EBITDA Margin % too high?
Gland Pharma's current EBITDA Margin % of 35.83% is near median its 10-year median of 36.90. Over the past 10 years, this metric has ranged from a low of 26.40 to a high of 42.53. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Gland Pharma's value of 35.83% is 189.2% above this industry median. Based on the distribution chart, Gland Pharma ranks #133 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #133 out of 955 companies for EBITDA Margin %. This places Gland Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Gland Pharma's value of 35.83% is 189.2% above this benchmark. Historically, Gland Pharma's own EBITDA Margin % has ranged from 26.40 to 42.53 over the past decade. While the company's 10-year median is 36.90 vs. the industry median of 12.39, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current EBITDA Margin % of 35.83% is 189.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current EBITDA Margin % is 35.83%, which is near median its own 10-year median of 36.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,124.86, compared to a current price of ₹2,314.80 — trading 8.9% above its estimated fair value. The current EBITDA Margin % is 35.83%, which is near median its 10-year median of 36.90 and 189.2% above the Drug Manufacturers industry median of 12.39. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current EBITDA Margin % is 35.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,314.80 is trading 8.9% above its estimated GF Value™ of ₹2,124.86.
GuruFocus considers Gland Pharma to be Fairly Valued.
Key valuation signals for NSE:GLAND:
EBITDA Margin %: 35.83% (near median its 10-year median of 36.90)
GF Value™: ₹2,124.86 vs. price of ₹2,314.80 (8.9% above fair value)
Industry Position: 189.2% above the Drug Manufacturers median (#133 of 955)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
